Business Context and Reporting Period
Company: Processa Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 19, 2018
Reporting Period: Specific event date (March 19, 2018); Company is an emerging growth company.
Key Financial Metrics
This filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses on a material definitive agreement and asset disposition.
Material Changes
- Agreement Execution: On March 19, 2018, Processa, Promet Therapeutics, LLC (Processa's largest shareholder), and Concert Pharmaceuticals, Inc. entered into an Amendment of the Option and License Agreement (originally dated October 4, 2017) and a Securities Purchase Agreement.
- Asset Transfer: Promet assigned the exclusive license for the asset CTP-499 from Concert to Processa.
- Share Transfer: Promet transferred 2,090,301 shares of Processa's common stock to Concert.
- Future Rights: Concert received a right of first offer to purchase new securities offered by Processa, contingent on Concert owning at least 2% of Processa's outstanding common stock.
- Revenue Rights: Concert will receive royalties on net sales received by Processa and on net sales received by sublicensees.
Guidance, Outlook, and Risks
Management Commentary: The filing describes the structural changes regarding the CTP-499 license and equity positions but does not provide forward-looking guidance, financial outlook, or specific risk factors beyond the standard qualification that the description of agreements is not complete.
Contingencies: Concert's right of first offer is contingent upon maintaining a 2% ownership stake in Processa.
Unusual Items: The transfer of a significant block of shares (2,090,301) from the largest shareholder to a third party in exchange for an exclusive license assignment is a notable corporate action.
Investor Verification Checklist
- Verify the full text of the Amendment of the Option and License Agreement and the Securities Purchase Agreement (referenced as exhibits to the Form 10-K for the year ended December 31, 2017).
- Confirm the current ownership percentage of Concert Pharmaceuticals, Inc. to validate the active status of the right of first offer.
- Review the specific royalty terms and calculation methods for CTP-499 net sales.
- Check subsequent filings for any press releases or updates regarding the commercialization status of CTP-499.